Brief introduction and clinical overview of Teritusumab/Telicat

Teritusumab (Teclistamab-cqyv ) is an innovative bispecific antibody drug that is a B-cell maturation antigen (BCMA)-directed CD3 T cell engager. The drug guides the patient's own immune system to directly attack myeloma cells by simultaneously binding to BCMA on the surface of tumor cells and CD3 molecules on the surface of T cells.

From the perspective of drug positioning, teritusumab is mainly used to treat adult patients with relapsed or refractory multiple myeloma. Such patients have usually received multiple lines of therapy, including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies, but the disease continues to progress and treatment options are relatively limited. In terms of its mechanism of action, Teritusumab does not rely on traditional cytotoxicity, but "bridges" T cells and myeloma cells by allowing T cells to be reactivated and accurately identify tumor targets. This mechanism allows it to still have therapeutic potential in highly drug-resistant populations, and also reflects the current development direction of immunotherapy from passive suppression to active immune activation.

From the perspective of clinical application, the advantage of teritusumab is that it does not require complex personalized cell preparation, and is easier to promote clinically than some cell therapy methods. Its subcutaneous injection delivery method also reduces the difficulty of treatment operations to a certain extent, making the patient's treatment process more continuous and controllable. In treatment practice, teritusumab is usually used in a highly standardized management system, including strict pre-medication assessment, incremental dose design, and close follow-up after medication. This systematic management model has gradually accumulated relatively stable application experience in the real world.

Overall, teritusumab represents the important direction of "bispecific antibodies" in the treatment of multiple myeloma It provides a new immunotherapy option for patients who have failed multiple lines of treatment, and also promotes the further upgrade of myeloma treatment strategies.

Keyword tags: Teritusumab Drug Introduction Telivac Bispecific Antibodies BCMA CD3 Multiple Myeloma Immunotherapy

Reference materials:https://go.drugbank.com/drugs/DB16655